{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:39:43Z","timestamp":1792449583728,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012249","name":"Jiangxi University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["CXTD22001"],"award-info":[{"award-number":["CXTD22001"]}],"id":[{"id":"10.13039\/501100012249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012249","name":"Jiangxi University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2023jzzdxk018"],"award-info":[{"award-number":["2023jzzdxk018"]}],"id":[{"id":"10.13039\/501100012249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejps.2026.107440","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:02:39Z","timestamp":1767945759000},"page":"107440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, synthesis, formulation, and bioevaluation of ZZP-2, a FLT3-ITD inhibitor for the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"218","author":[{"given":"Wentao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwa","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weike","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7539-9502","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107440_bib0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jconrel.2016.04.019","article-title":"Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer","volume":"232","author":"Adjei","year":"2016","journal-title":"J. Controll. Rel."},{"key":"10.1016\/j.ejps.2026.107440_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101318","article-title":"Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research","author":"Bubnova","year":"2025","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejps.2026.107440_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121461","article-title":"SEDDS facilitate cinnamaldehyde crossing the mucus barrier: the perspective of mucus and Caco-2\/HT29 co-culture models","volume":"614","author":"Cai","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2026.107440_bib0004","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2022.2155638","article-title":"Design, synthesis and evaluation of 2, 6, 8-substituted imidazopyridine derivatives as potent PI3K\u03b1 inhibitors","volume":"38","author":"Chen","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejps.2026.107440_bib0005","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1039\/D1CS00755F","article-title":"Delivery strategies in treatments of leukemia","volume":"51","author":"Ci","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"10.1016\/j.ejps.2026.107440_bib0006","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"10393","key":"10.1016\/j.ejps.2026.107440_bib0007","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"Dinardo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2026.107440_bib0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejpb.2021.03.001","article-title":"Imine bond formation as a tool for incorporation of amikacin in self-emulsifying drug delivery systems (SEDDS)","volume":"162","author":"Dizdarevic","year":"2021","journal-title":"Eur. J. Pharmaceut. Biopharmaceut."},{"issue":"12","key":"10.1016\/j.ejps.2026.107440_bib0009","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Doehner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejps.2026.107440_bib0010","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/ajh.25975","article-title":"Acute myeloid leukemia: 2021 update on risk-stratification and management","volume":"95","author":"Estey","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejps.2026.107440_bib0011","unstructured":"FDA, 2006. SUTENT\u00ae (sunitinib malate) capsules https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021968s002s003s004s005s006lbl.pdf."},{"key":"10.1016\/j.ejps.2026.107440_bib0012","unstructured":"FDA, 2017. Xospata\u00ae (gilteritinib) product quality review(S). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211349Orig1s000ChemR.pdf."},{"issue":"1","key":"10.1016\/j.ejps.2026.107440_bib0013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107440_bib0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","article-title":"The structural basis for autoinhibition of FLT3 by the juxtamembrane domain","volume":"13","author":"Griffith","year":"2004","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.ejps.2026.107440_bib0015","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1021\/acs.molpharmaceut.8b00482","article-title":"Inhibitory effects of commonly used excipients on P-glycoprotein in vitro","volume":"15","author":"Gurjar","year":"2018","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.ejps.2026.107440_bib0016","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","article-title":"NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells","volume":"100","author":"Ito","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejps.2026.107440_bib0017","first-page":"336","article-title":"Enhanced intestinal lymphatic absorption of saquinavir through supersaturated self-microemulsifying drug delivery systems","volume":"15","author":"Jo","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2026.107440_bib0018","first-page":"96","article-title":"Liposomal formulations for enhanced lymphatic drug delivery","volume":"8","author":"Kim","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2026.107440_bib0019","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107440_bib0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.xphs.2020.07.024","article-title":"Lysine-based biodegradable surfactants: increasing the lipophilicity of insulin by hydrophobic ion paring","volume":"110","author":"Kurpiers","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.ejps.2026.107440_bib0021","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25620","article-title":"Maintenance therapy in AML: the past, the present and the future","volume":"94","author":"Molica","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.ejps.2026.107440_bib0022","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jconrel.2011.11.020","article-title":"Bone metastasis targeting: a novel approach to reach bone using zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel","volume":"158","author":"Ramanlal Chaudhari","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejps.2026.107440_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.ejps.2026.107440_bib0024","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-020-01077-1","article-title":"Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo","volume":"35","author":"Rummelt","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejps.2026.107440_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3322\/caac.21874","article-title":"Ca-a cancer journal for","volume":"75","author":"Saka","year":"2025","journal-title":"Clinicians"},{"issue":"8","key":"10.1016\/j.ejps.2026.107440_bib0026","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejps.2026.107440_bib0027","doi-asserted-by":"crossref","first-page":"21752","DOI":"10.1021\/acs.jmedchem.4c00529","article-title":"Discovery of SILA-123 as a highly potent FLT3 inhibitor for the treatment of acute myeloid leukemia with various FLT3 mutations","volume":"67","author":"Wei","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107440_bib0028","article-title":"Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)pyridine derivatives as novel FLT3-ITD inhibitors","volume":"289","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107440_bib0029","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijpharm.2018.11.010","article-title":"Development and in vitroevaluation of a self-emulsifying drug delivery system (SEDDS) for oral vancomycin administration","volume":"554","author":"Zaichik","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2026.107440_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpharm.2011.05.054","article-title":"Characterisation of the interactive properties of microcrystalline cellulose-carboxymethyl cellulose hydrogels","volume":"415","author":"Zhao","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107440_bib0031","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.2147\/IJN.S51578","article-title":"Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation","volume":"8","author":"Zhao","year":"2013","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.ejps.2026.107440_bib0032","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1038\/s41467-022-33143-w","article-title":"Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872600014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872600014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:49:55Z","timestamp":1772491795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872600014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"alternative-id":["S092809872600014X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107440","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, formulation, and bioevaluation of ZZP-2, a FLT3-ITD inhibitor for the treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107440"}}